Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: Cancer Res. 2010 Aug 31;70(20):8036–8044. doi: 10.1158/0008-5472.CAN-10-1366

Figure 5. 1t selectively suppresses the growth of BRAF mutant tumors in vivo.

Figure 5

(A) Mice bearing established A375M xenografts were treated with 1t p.o. with daily dosing (20 mg/kg) for 24 d and tumor size was monitored every 3-4 d. Mean tumor volume is plotted ± SEM (n=8 mice per group). (B) A375M tumors were established as above and mice were treated with a single oral dose of 20 mg/kg 1t. After 4 h, tumors were harvested and lysates were analyzed by quantitative fluorescent Western blotting for MEK1/2 phosphorylation and total MEK1. (C) Mice bearing SW620 xenografts were treated as in (A) for 23 d and tumor size was monitored every 3-4 d. (D) Mice bearing SW620 tumors received a single p.o. dose of vehicle or 1t (20 mg/kg) and tumors were harvested 4 h post-dosing. Tumor lysates were analysed for MEK phosphorylation as in (B).